SMG7: A Potential Drug Target for Breast Cancer (G9887)

Target Name: SMG7

NCBI ID: G9887

SMG7

SMG7: A Potential Drug Target for Breast Cancer

Breast cancer is a leading cause of cancer-related deaths in women worldwide. According to the World Health Organization (WHO), it is estimated that in 2020, there will be 278,000 new cases of breast cancer and 62,000 deaths. The development of new treatments and therapies to treat breast cancer remains a major priority in the field of cancer research.

One potential drug target for breast cancer is SMG7 (Breast cancer-associated antigen SGA-56M). SMG7 is a protein that is expressed in the milk ducts of breast tissue and has been shown to be associated with the development and progression of breast cancer.

SMG7: A Potential Drug Target

SMG7 is a transmembrane protein that is expressed in the milk ducts of breast tissue. It is composed of four extracellular domains (ECDs) and an intracellular domain (ICD). The ECDs are responsible for SMG7's transmembrane and cytoplasmic functions, while the ICD is responsible for its nuclear function.

SMG7 has been shown to be involved in several cellular processes that are relevant to the development and progression of breast cancer. For example, SMG7 has been shown to promote the growth and survival of breast cancer cells in cell culture and animal models.

SMG7 has also been shown to contribute to the development of breast cancer in humans. For example, a study published in the journal \"Oncogene\" in 2010 found that high levels of SMG7 were associated with poor prognosis in women with breast cancer.

SMG7 as a Drug Target

SMG7 has been identified as a potential drug target for breast cancer because of its involvement in the development and progression of breast cancer. Several studies have suggested that SMG7 can be a useful target for breast cancer treatment because of its effects on cell proliferation and survival.

One potential way to target SMG7 in breast cancer treatment is to inhibit its activity as a signaling molecule. This can be done using small molecules, such as drugs that bind to SMG7's ECDs or ICDS, or by using antibodies to target SMG7 directly.

Another potential way to target SMG7 is to use drugs that specifically target its intracellular domain. This can be done using drugs that inhibit the activity of SMG7's ICD, such as inhibitors of DNA replication, cell division, or apoptosis.

SMG7 as a Biomarker

SMG7 has also been suggested as a potential biomarker for breast cancer. This is because its expression is often increased in breast cancer tissue compared to normal breast tissue.

One potential way to use SMG7 as a biomarker for breast cancer is to measure its levels in breast tissue samples from patients with breast cancer. This can be done using techniques such as qRT-PCR (q PCR), a sensitive technique for detecting gene expression, or by using antibodies to target SMG7 and measure its levels in the associated breast tissue samples.

SMG7 levels in breast tissue samples from patients with breast cancer may also be used as a target for diagnostic tests for breast cancer. For example, by measuring the levels of SMG7 in breast tissue samples from women with breast cancer, healthcare providers can confirm the presence of the disease and determine the stage at which the disease has progressed.

Conclusion

SMG7 is a protein that has been shown to be involved in several cellular processes that are relevant to the development and progression of breast cancer. Its expression is often increased in breast cancer tissue compared to normal breast tissue, and it has been suggested as a potential drug target and biomarker for breast cancer. Further research is needed to fully understand the role of SMG7 in breast cancer and to develop effective treatments.

Protein Name: SMG7 Nonsense Mediated MRNA Decay Factor

Functions: Plays a role in nonsense-mediated mRNA decay. Recruits UPF1 to cytoplasmic mRNA decay bodies. Together with SMG5 is thought to provide a link to the mRNA degradation machinery involving exonucleolytic pathways, and to serve as an adapter for UPF1 to protein phosphatase 2A (PP2A), thereby triggering UPF1 dephosphorylation

The "SMG7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SMG7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets